患有血液癌症的儿童中COVID-19感染:系统性审查
Saad Alhumaid1, Khalid Al Noaim2, Anwar A Almuslim3
1School of Pharmacy, University of Tasmania, Hobart, 7000, Australia. saalhumaid@moh.gov.sa.
Annals of hematology
|November 4, 2024
概括
患有血液癌症的儿童容易感染COVID-19,白血病是最常见的类型. 虽然有些人面临更高的ICU入院和死亡风险,但大多数人经历了轻微的症状,这表明继续治疗癌症是可能的.
科学领域:
- 儿科瘤学 儿科瘤学
- 传染性疾病 传染性疾病
- 血液学 血液学 血液学
背景情况:
- 血液癌症是儿童癌症死亡的主要原因之一.
- 患有血液癌症的儿童患有COVID-19等病毒感染的严重后果的风险增加.
结论:
- 与健康儿童相比,感染SARS-CoV-2的血液癌症儿童可能会增加ICU入院和死亡风险.
- 尽管存在风险,但患有血液癌症的儿童通常会比成年人体验更轻微的COVID-19症状和更好的预后.
- 在COVID-19感染期间继续进行抗癌治疗对于许多儿科患者来说似乎是可行的.
相关概念视频
Bone Marrow Sampling and Transplants
292
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
292
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K


